monoclonal antibodies News
-
License agreement with Research Development Foundation for two monoclonal antibodies for oncology
Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton de la Recherche. During the past 10+ years Institut Clayton de la Recherche has funded research at the laboratories of Prof. Beat Imhof and Thomas ...
By Abologix
-
Evotec Biologics awarded contract from U.S. Department of Defense under accelerated antibodies program
Evotec SE have announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody (“mAb”)-based drug product prototypes targeting plague. Plague, an infectious disease caused by the bacterium... READ MORE ...
-
Creative Diagnostics Expands Its Monoclonal Antibodies Offering to Customers
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. Monoclonal antibodies (mAbs) are generated by identical B cells that are cloned from a single parent cell. ...
-
SARS-Cov-2 Antigen Rapid Test Kits
CARDIMED B.V. is the official distributor for the SARS-Cov-2 Antigen Rapid Test Kits (Lepu Medical) in the Netherlands. The advantages at a glance: Non-invasive Easy to use Convenient, no equipment required Fast, get a result in 15 minutes Stable, with high accuracy Cost-effective, cost-efficient The test card contains a gold-labeled novel coronavirus N protein monoclonal antibody pre-coated ...
-
MiLaboratories LLC launches TCR profiling for non-human primates
Service available for rhesus macaque (Macaca mulatta) and cynomolgus (crab-eating macaque, Macaca fascicularis). Phylogenetic closeness to humans makes non-human primates a model of choice for assessing the safety and efficiency of novel monoclonal antibodies and immunotherapeutic approaches. UMI-based TCR profiling allows to track the clonotype fates and alterations in TCR repertoire with the ...
-
ABOLOGIX awarded a two year Innosuisse Innovation
Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule JAM-C by monoclonal antibodies supplied ...
By Abologix
-
Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have five poster presentations at the SITC 2022 Annual Meeting being held in Boston, Massachusetts from November 8-12. The posters will highlight preclinical studies on five ...
By Elpiscience
-
Optimizing Monoclonal Antibody Production: Temperature And Osmolality’s Impact, Upcoming Webinar Hosted By Xtalks
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
-
Covid-19 vaccine candidates using SpyCatcher/SpyTag to display Spike protein on computationally designed particles and Bacteriophage VLPs
recent papers with really interesting results! Click here to read the full paper on computationally designed VLPs. Results: RBD can be efficiently displayed on the mi3 VLP via SpyTag/SpyCatcher RBD-SpyVLP is reactive to monoclonal antibodies isolated from recovered patients RBD-SpyVLP induces a strong ACE2-blocking and neutralising antibody response in mouse models RBD-SpyVLP is highly ...
-
ABOLOGIX founded in Geneva, Switzerland
Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland). The three founders of Abologix are Dr.Ignacio Faus, Prof. Beat Imhof and Prof. Thomas Matthes.The company intends to develop novel monoclonal antibodies for the treatment of JAM-C positive hematological tumours.New therapeutics for the treatment of difficult to manage ...
By Abologix
-
Agilent Technologies Introduces New Column Innovations for Biotherapeutics Development
Agilent Technologies Inc. (NYSE: A) today introduced the AdvanceBio RP-mAb, a reversed-phase column optimized to separate monoclonal antibodies. The AdvanceBio RP-mAb-the latest in a series of products in the AdvanceBio family-is part of Agilent's extensive R&D effort to support biological research and drug development by increasing the accuracy and productivity of biocolumns technology. ...
-
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
Ad Hoc Release Pursuant to Art. 53 Listing Rules Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply ...
-
U.S. FDA Extends Review of Biologics License Application for REGEN-COV (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure ...
-
Pronalyse Unveils Insightful Metabolite Identification Services of Biopharmaceuticals
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its metabolite identification services of biopharmaceuticals for an accurate and efficient analysis of the metabolism for your biological drugs in vivo. The ...
-
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal ...
-
AbCellera’s statement on the neutralization activity of its monoclonal antibody therapies against the Omicron variant of concern
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant. The data confirmed that the investigational antibody bebtelovimab, which is currently in Phase 2 clinical trials with our partner, Eli Lilly and Company (Lilly), ...
-
Vybion New Drug Webinar for Huntington`s Patients
Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. The company believes that Intrabodies can achieve both the specificity and safety of ...
By Vybion
-
Abologix obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model. In this study the efficacy of rH225 was tested by assessing: the delayed mortality upon Jeko-1 MCL cell injection and the reduction of Jeko-1 cells burden in the blood, spleen, lymph nodes, bone marrow and liver rH225 delayed ...
By Abologix
-
Pronalyse Launches Antibody Drug Conjugates (ADCs) Characterization Service for Drug Discovery
Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs. In recent years, there has been a global upsurge in the research ...
-
Vybion Huntington`s Disease Drug Patent receives Track I Status
Vybion, Inc. is pleased to announce that its patent application covering methods of use and composition for INT41 Gene Therapy received Track I status from the USPTO. The INT41 patent application covers several neurodegenerative diseases in addition to Huntington's Disease including Spinal Cerebellar Ataxia, Spinal Muscular Atrophy, and Alzheimer's. "Vybion is pleased to receive Track I status on ...
By Vybion
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you